Fatih Kus
Overview
Explore the profile of Fatih Kus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
8
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yay F, Yildirim H, Kus F, Yalcin S
Biomarkers
. 2025 Jan;
:1-20.
PMID: 39847517
Background: Dynamins are defined as a group of molecules with GTPase activity. Among them, DNM3 has gained recognition in oncology for its tumor suppressor role. Based on this, the aim...
2.
Tunbekici S, Yuksel H, Acar C, Sahin G, Orman S, Majidova N, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796675
Background/objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate...
3.
Degerli E, Arslan C, Selcukbiricik F, Olmez O, Erdem D, Hamdard J, et al.
Medicina (Kaunas)
. 2025 Jan;
60(12.
PMID: 39768982
: A high baseline neutrophil-to-lymphocyte ratio (NLR) is a poor prognostic factor in various cancers. However, its predictive role in metastatic bladder cancer (mBC) treated with immunotherapy is unclear. In...
4.
Kus F, Guven D, Yildirim H, Akagunduz B, Karakaya S, Sutcuoglu O, et al.
Integr Cancer Ther
. 2024 Oct;
23:15347354241280273.
PMID: 39367737
Aims: This study aimed to assess the habits and knowledge of cancer patients regarding the use of herbal medicines and dietary supplements in cancer patients receiving immune checkpoint inhibitors (ICI)....
5.
KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer
Kus F, Guven D, Yildirim H, Chalabiyev E, Akyildiz A, Tatar O, et al.
Biomark Med
. 2024 Aug;
18(10-12):511.
PMID: 39136458
No abstract available.
6.
Yildirim H, Buyukkor M, Kavgaci G, Celik B, Yucel K, Dursun B, et al.
Medicine (Baltimore)
. 2024 Jul;
103(30):e38828.
PMID: 39058877
The fact that the human epidermal growth factor receptor 2 (HER2)-low group, historically classified as HER2 negative in breast cancer histology, benefited from HER2-targeted treatments similarly to the HER2-positive group...
7.
Akyildiz A, Ismayilov R, Guven D, Yildirim H, Tatar O, Kus F, et al.
Vascular
. 2024 Mar;
:17085381241241853.
PMID: 38523367
Aim: Sirolimus, a mammalian target of rapamycin inhibitor, inhibits cell growth and proliferation by controlling ribosome biogenesis and protein synthesis in vascular anomalies and cancers. However, most sirolimus studies on...
8.
Yildirim H, Kutlu Y, Mutlu E, Aykan M, Korkmaz M, Yalcin S, et al.
Int J Clin Oncol
. 2024 Feb;
29(3):258-265.
PMID: 38310597
Introduction: Male breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of...
9.
Yildirim H, Kus F, Guven D, Karaca E, Kaygusuz Y, Dizdar O, et al.
J Immunother Precis Oncol
. 2023 Dec;
6(4):170-176.
PMID: 38143956
Introduction: Although immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, identifying factors that predict treatment response remains a challenge in clinical practice. There is a need for biomarkers...
10.
KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer
Kus F, Guven D, Yildirim H, Chalabiyev E, Akyildiz A, Tatar O, et al.
Biomark Med
. 2023 Jun;
17(7):379-389.
PMID: 37309756
To assess the prognostic role of the CA-125 elimination rate constant K (KELIM) score in platinum-resistant/refractory ovarian cancer patients receiving second-line treatment. A retrospective study was carried out including 117...